Ardis first described the synthesis of cyanoacrylates in 1949,1 and since that time, its use for applications such as wound closure, skin grafts, and organ anastomoses has been investigated.2,3 N-butyl cyanoacrylate (NBCA) has been used since the 1980s as a liquid embolic material, mainly for neurointerventional indications; it was approved in the United States by the U.S. Food and Drug Administration for use in cerebral arteriovenous malformations in 2000. Since that time, its use in the periphery has grown significantly. Presently, glue is one of the most important and indispensable embolic materials in interventional radiology. NBCA is approved as a medical device in most countries, but its approval for embolization varies from country to country. Therefore, it is often used off-label for embolization.
NBCA is a liquid embolic agent that consists of a two-carbon ethylene molecule with a cyano group and an ester (carbonyl group) attached to one of the carbons; the ester in NBCA is attached to an N-butyl hydrocarbon.4,5Polymerization occurs upon contact with any ionic substances (e.g., blood, saline, ionic contrast media, and vessel endothelium) due to bonding of the ethylene units after exposure to an anion (such as a hydroxyl group).1 Because of this mechanism, NBCA is able to flow through the vasculature to the target lesion as a liquid but leads to embolization once it polymerizes and becomes solid.
Once administered, the polymerization process causes the release of formaldehyde, which can contribute to the toxicity of NBCA. The extent of the toxicity depends on the size of the side chain ester; NBCA is less toxic than methyl and ethyl cyanoacrylates.6 Embolization with NBCA leads to an acute inflammatory response in the vessel wall and surrounding tissue.1 With time, this leads to a chronic granulomatous inflammatory process.7–9
To use NBCA appropriately as an embolic agent in interventional procedures, there are two points to keep in mind: visualization under image guidance and control of the polymerization time. Both of these points can be addressed with the use of iodized oil (Lipiodol), which can be mixed with NBCA at any ratio to make it visible under fluoroscopy and to increase its polymerization time and viscosity (Figs. 9.1and 9.2).10 The dilution rate is usually 10% to 50% (NBCA/Lipiodol) for most clinical indications.
The viscosity of the NBCA–Lipiodol mixture becomes higher upon contact with blood and endothelium in vessels. This ultimately leads to vascular occlusion once blood flow cannot push the mixture due to its high viscosity. This mechanism of embolization is different when compared with materials such as microspheres, polyvinyl alcohol (PVA), and gelatin sponge, which typically occlude vessels at a level within the vasculature, which matches the size of the embolic agent. An NBCA–Lipiodol mixture also stops at the point of branching vessels once the mixture cannot get into smaller vessels due to its high viscosity. Therefore, high-concentration NBCA–Lipiodol mixtures with a dilution rate of 40% to 50% can be used for proximal embolization. Dilution rates of 10% to 20% can be used to embolize long and branching vessels (Fig. 9.3). However, when compared with particles measuring 100 to 500 µm in diameter, an NBCA–Lipiodol mixture leads to a more proximal embolization.
When preparing the mixture of NBCA and Lipiodol, attention is required to avoid any contact between NBCA and Lipiodol and any ionic substance.5 The author always aspirates NBCA from the NBCA ampule directly into a new syringe with a new needle and then aspirates the desired volume of Lipiodol into the same syringe. If a high-diluted NBCA–Lipiodol is to be prepared, a second Lipiodol-containing syringe should be prepared, and both should be mixed to obtain the target dilution rate for the NBCA–Lipiodol mixture (Fig. 9.4). To avoid polymerization, the NBCA–Lipiodol mixture should not be allowed to be in contact with room air for long period. The syringe containing the NBCA–Lipiodol mixture should therefore be capped at all times. The author usually uses the mixture within 10 minutes after preparation.
When injecting the NBCA–Lipiodol mixture, a coaxial catheter system must be used because it is difficult to control the injection with a larger lumen catheter. When the coaxial microcatheter tip reaches the target point, a test injection of contrast is performed to confirm the position of catheter tip and to assess blood flow. The catheter is then flushed with a 5% glucose solution to clear all contrast from the inner lumen.5,11 This is an important step in the use of NBCA because it is difficult to distinguish the NBCA–Lipiodol mixture from contrast under fluoroscopy. Clearing the contrast from the catheter after the test injection allows the operator to confirm when NBCA is being administered. Three seconds after an optimal amount of NBCA–Lipiodol has been injected, the microcatheter should be removed to minimize the risk that the tip of the catheter will adhere to the vessel wall. A small amount of time is needed because if the catheter is removed too quickly, the risk of backflow of unpolymerized NBCA can occur due to the negative pressure caused by catheter removal. If the intent of the procedure is to inject a fixed amount of NBCA–Lipiodol mixture, it is possible to push the mixture with 5% glucose. Following embolization, the microcatheter should be disposed of immediately because the polymerized NBCA–Lipiodol mixture may remain in the lumen of the catheter. It may be possible to flush the catheter with sufficient volume of Lipiodol and 5% glucose if necessary.11 If a guidewire can be passed without any resistance after flushing, the author sometimes uses the same microcatheter system.
Based on its special features, the use of NBCA as an embolic agent is theoretically indicated for the following three situations. First, it is optimal to occlude a vessel with multiple branches or communications to other vessels. For example, NBCA can be used to embolize atypical vessels responsible for the arterial supply to liver tumors, such as the inferior phrenic artery. The inferior phrenic artery is rather long and has many communications with other arteries (e.g., intercostal arteries, internal mammary artery, etc.). Given the potential territory supplied by this vessel, NBCA is an effective agent to use for embolization in this situation (Fig. 9.5). For this reason, NBCA is a commonly used agent for the treatment of arteriovenous malformations (Fig. 9.6).12 Second, NBCA is used to occlude target vessels when the catheter position is unstable. Catheter stability is very important when using coils for embolization because catheters are under tension when coils are being introduced. If a coil is inserted through a catheter with an unstable position, the catheter tip may move back and forth, which can lead to coil migration into an unexpected or undesired location. Instead of coils, NBCA–Lipiodol mixture can be used in this scenario because it comes out of the catheter in a few seconds. This may often be the case when embolizing a right gastric artery for the purpose of redistribution for hepatic infusion chemotherapy and yttrium 90 infusion (Fig. 9.7),13 portal vein branches for preoperative portal vein embolization (Fig. 9.8),14–16 or a bronchial artery in patients with hemoptysis (Fig. 9.9).17 NBCA has also been shown to be an effective agent to treat gastrointestinal bleeding.18 Third, NBCA–Lipiodol can potentially be a more effective embolic agent than coils or particles in coagulopathic patients.19,20 Coils and particles rely on normal coagulation for vessel occlusion. Therefore, if a patient with bleeding is coagulopathic, coils or particles may not help to stop the bleeding. However, NBCA mixture can mechanically occupy the intravascular lumen and stop blood flow regardless of blood coagulability.
An NBCA–Lipiodol mixture can be also used for nonvascular applications. This mixture is suitable for tract embolization to avoid bleeding from the tract of blood-rich organ. This may be done in association with percutaneous biopsy or ablation procedures. The author usually uses NBCA–Lipiodol mixture after the transsplenic interventions to prevent bleeding from the spleen (Fig. 9.10).
Rosen and Contractor1 defined the complications of NBCA administration as either being associated with the actual administration of the liquid agent or being associated with the anatomy of the target vasculature. More specifically, this can include occlusion of normal territory due to misinterpretation of anatomy, distal migration or reflux of embolic material, or artery-to-artery anastomoses; migration of embolic material to the venous side of the target vascular bed; and catheter gluing.21
Migration of embolic material to the venous side of a malformation can potentially lead to venous hypertension or pulmonary emboli. Given the fact that close fluoroscopic monitoring is typically employed during an NBCA embolization, the likelihood of a large volume of material passing into the pulmonary circulation is low. Therefore, this complication is not typically clinically significant.22
The gluing of the delivery catheter to the vessel wall is a rare phenomenon that can be minimized with the use of hydrophilic microcatheters and NBCA at lower concentrations. It is often due to reflux of NBCA during embolization, early polymerization, or a failure to retract the microcatheter in an appropriate amount of time.5 In general, a quick tug on the microcatheter is often able to separate a microcatheter from a glue cast due to the relatively low tensile strength of the polymerized NBCA.1
TIPS AND TRICKS
• There are two colors of NBCA available. One is blue and the other is clear. When using the clear NBCA, it is important to label the syringe to prevent it from being confused with contrast or saline.
• To avoid undesirable distribution of an NBCA–Lipiodol mixture, coils can be deployed in vessels which require protection before NBCA administration (see Fig. 9.10).
• To embolize a long vessel with NBCA, optimal embolization can be obtained by pulling back the microcatheter from the distal to the proximal portion of the vessel during injection (Fig. 9.11). Using this technique, a vessel with multiple branches or communications to other vessels can be entirely occluded.
NBCA is a very useful embolic agent for interventional radiologists in various clinical applications. Its mechanism of embolization is different from that of other materials, and there are many technical steps required for the appropriate handling and administration of NBCA. Acquiring sufficient knowledge and skills of controlling this unique embolic agent will allow for its successful use.
1. Rosen RJ, Contractor S. The use of cyanoacrylate adhesives in the management of congenital vascular malformations. Semin Intervent Radiol. 2004;21:59–66.
2. Galil KA, Schonfield ID, Wright GZ. Effect of butyl 2-cyanoacrylate on the healing of skin wounds. J Can Dent Assoc. 1984;50:565–569.
3. Petrella E, Orlandini G, Poisetti P, et al. A new end to side anastomosis formed without sutures for hemodialysis fistulas. Nephron. 1975;14:398–400.
4. Kerber CW, Wong W. Liquid acrylic adhesive agents in interventional neuroradiology. Neurosurg Clin N Am. 2000;11:85–99.
5. Pollak JS, White RI. The use of cyanoacrylate adhesives in peripheral embolization. J Vasc Interv Radiol. 2001;12:907–913.
6. Schweitzer JS, Chang BS, Madsen P, et al. The pathology of arteriovenous malformations of the brain treated by embolotherapy. Neuroradiology. 1993;35:468–474.
7. Brothers MF, Kaufman JC, Fox AJ, et al. N-butyl 2-cyanoacrylate substitute for IBCA in interventional neuroradiology: histopathological and polymerization time studies. Am J Neuroradiol. 1989;10:777–786.
8. White RI, Strandberg JV, Gross GS, et al. Therapeutic embolization with long-term occluding agents and their effects on embolized tissues. Radiology. 1977;125:677–687.
9. Vinters HV, Galil KA, Lundie MJ, et al. The histotoxicity of cyanoacrylates: a selective review. Neuroradiology. 1985;27:279–291.
10. Takasawa C, Seiji K, Matsunaga K, et al. Properties of N-butyl cyanoacrylate-iodized oil mixtures for arterial embolization: in vitro and in vivo experiments. J Vasc Interv Radiol. 2012;23:1215–1221.
11. Moore C, Murphy K, Gailloud P. Improved distal distribution of n-butyl cyanoacrylate glue by simultaneous injection of dextrose 5% through the guiding catheter: technical note. Neuroradiology. 2006;48:327–332.
12. Lee BB, Do YS, Yakes W, et al. Management of arteriovenous malformations: a multidisciplinary approach. J Vasc Surg. 2004;39:590–600.
13. Arai Y, Takeuchi Y, Inaba Y, et al. Percutaneous catheter placement for hepatic arterial infusion chemotherapy. Tech Vasc Interv Radiol. 2007;10:30–37.
14. De Baere T, Denys A, Paradis V. Comparison of four embolic materials for portal vein embolization: experimental study in pigs. Eur Radiol. 2009;19:1435–1442.
15. Denys A, Lacombe C, Schneider F, et al. Portal vein embolization with N-butyl cyanoacrylate before partial hepatectomy in patients with hepatocellular carcinoma and underlying cirrhosis or advanced fibrosis. J Vasc Interv Radiol. 2005;16(12):1667–1674.
16. Guiu B, Bize P, Gunthern D, et al. Portal vein embolization before right hepatectomy: improved results using n-butyl-cyanoacrylate compared to microparticles plus coils. Cardiovasc Intervent Radiol. 2013;36:1306–1312.
17. Razavi MK, Murphy K. Embolization of bronchial arteries with n-butyl cyanoacrylate for management of massive hemoptysis: a technical review. Tech Vasc Interv Radiol. 2007;10:276–282.
18. Yata S, Ihava T, Kaminou T, et al. Transcatheter arterial embolization of acute arterial bleeding in the upper and lower gastrointestinal tract with n-butyl 2-cyanoacrylate. J Vasc Interv Radiol. 2013;24:422–431.
19. Yonemitsu T, Kawai N, Sato M, et al. Comparison of hemostatic durability between n-butyl cyanoacrylate and gelatin sponge particles in transcatheter arterial embolization for acute arterial hemorrhage in a coagulopathic condition in a swine model. Cardiovasc Intervent Radiol. 2010;33;1192–1197.
20. Yonemitsu T, Kawai N, Sato M, et al. Evaluation of transcatheter arterial embolization with gelatin sponge particles, microcoils, and n-butyl cyanoacrylate for acute arterial bleeding in a coagulopathic condition. J Vasc Interv Radiol. 2009;20:1176–1187.
21. Niimi Y, Berenstein A, Setton A. Complications and their management during NBCA embolization of craniospinal lesions. Int Neuroradiol. 2003;9(suppl 1):157–164.
22. Pelz DM, Lownie SP, Fox AJ, et al. Symptomatic pulmonary complications from liquid acrylate embolization of brain arteriovenous malformations. Am J Neuroradiol. 1997;16:19–26.